Kartamethasone 1.5
Composition:
Each tablet contains: Dexamethasone 1.5 mg.
Indications:
1- Endocrine disorders: primary or secondary, adrenocortical insufficiency congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypercalcaemia associated with cancer
2- Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus ;acute rheumatic carditis.
3- Rheumatic disorders: as adjunctive therapy for short-term administration in: rheumatioid arthritis, psoriatic arthritis, ankylosing spondylitis, acute and subacute bursitis; acute nonspecific tenosynovitis ;acute gouty arthritis; posttraumatic; osteoarthritis.
4- Dermatologic diseases: pemphigus, bullous dermatitis herpetiformis; exfoliative dermatitis, mycosis fungoides, erythema multiforme, severe psoriasis ;sever seborrheic dermatitis.
5- Allergic states: Seasonal or perennial allergic rhinitis, bronichial asthma, contact and atopic dermatitis, drug hypersensitivity reactions.
6- Ophthalmic diseases: allergic conjunctivitis, keratitis, herpes zoster ophthalmicus, iritis, chorioretinitis, optic neuritis.
7- Respiratory disease: Symptomatic sarcoidosis, loeffler’s syndrome, berylliosis ;fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy ;aspiration pneumonitis .
8- Hematologic diseases: idiopathic and secondary thrombocytopenic purpura in adults, autoimmune hemolytic anemia, erythroblastopenia, congential hypoplastic anemia.
9- Neoplastic Diseases: Leukemias and lymphomas in adults ;acute leukemia of childhood.
10- Edematous states: to induce a diuresis or remission of proteinuria in the nephritic syndrome without uremia.
11- Gastrointestinal diseases: to tide that patient over a critical period of the disease in: ulcerative colitis, regional enteritis.
12 –Cerebral Edema: Associated with primary or metastatic brain tumor ,craniotomy ,or head injury .Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy.
13-Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy, trichinosis.
Dosage and Administration
Dosage requirements are variable and must be individualized on the basis of the disease and response of the patient.
The initial dosage varies from 0.75-9 mg a day depending on the disease being treated .In less severe diseases dose lower than 0.75 mg may suffice, while in severe diseases doses higher than 9 mg may be required. The initial dosage should be maintained or adjusted until the patient’s response is satisfactory .If satisfactory clinical response dose not occur after a reasonable period of time ,discontinue Dexamethasone and transfer the patient to other therapy.
After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response.
Patients should be observed closely for signs that might require dosage adjustment , including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness , and the effect of stress (e.g: surgery, infection, trauma ). During stress it may be necessary to increase dosage temporarily.
If the drug is to be stopped after more than a few days of treatment ,it usually should be withdrawn gradually.
Package:
Carton box contains 30 tablets of each strength.
